

## OTREXUP - (10MG/0.4ML, 15MG/0.4ML, 20MG/0.4ML, 25MG/0.4ML, 7.5MG/0.4ML, 12.5MG/0.4ML, 17.5MG/0.4ML, 22.5MG/0.4ML)

<b>Generic Name</b>	METHOTREXATE	<b>Innovator</b>	ASSERTIO Therapeutics
<b>Dosage</b>	10MG/0.4ML, 15MG/0.4ML, 20MG/0.4ML, 25MG/0.4ML, 7.5MG/0.4ML, 12.5MG/0.4ML, 17.5MG/0.4ML, 22.5MG/0.4ML	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Otrexup is a folate analog metabolic inhibitor indicated for the: • Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), who are intolerant of or had an inadequate response to first-line therapy. • Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events



Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.